Enhancement of oral bioavailability of cyclosporine A: Comparison of various nanoscale drug-delivery systems

International Journal of Nanomedicine

Volumn 9, Issue , 2014, Pages 4991-4999

  Wang, Kai ^a,b,c   Qi, Jianping ^a   Weng, Tengfei ^a,b   Tian, Zhiqiang ^a   Lu, Yi ^a   Hu, Kaili ^d   Yin, Zongning ^b   Wu, Wei ^a  

^a FUDAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c INSTITUTE OF TROPICAL BIOSCIENCE AND BIOTECHNOLOGY   (China)

^d SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Bioavailability; Cyclosporine A; Nanostructured lipid carrier; PLGA nanoparticle; Self microemulsifying drug delivery systems

Indexed keywords

CYCLOSPORIN A; NANOPARTICLE; POLYGLACTIN; CYCLOSPORIN; DRUG CARRIER; EMULSION;

ADULT; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BEAGLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; IN VITRO STUDY; IN VIVO STUDY; LIPID COMPOSITION; LIPOSOMAL DELIVERY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; SELF MICROEMULSIFYING DRUG DELIVERY SYSTEM; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOAVAILABILITY; BLOOD; CHEMISTRY; DOG; EMULSION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; DOGS; DRUG CARRIERS; EMULSIONS; MALE; NANOPARTICLES;

EID: 84930243640     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S72560     Document Type: Article

References (51)

1. Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol. 2008; 36(1): 43-48.
2. Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm. 2011; 420(1): 1-10.
3. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995; 12(3): 413-420.
4. Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, Ali J. Nanostructured lipid carriers system: recent advances in drug delivery. J Drug Target. 2012; 20(10): 813-830.
5. Cao X, Gibbs ST, Fang L, et al. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res. 2006; 23(8): 1675-1686.
6. Xu Y, Liu X, Lian R, et al. Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/homogenization based on acid-base neutralization. Int J Pharm. 2012; 438(1-2): 287-295.
7. Fatma S, Talegaonkar S, Iqbal Z, et al. Novel flavonoid-based biodegradable nanoparticles for effective oral delivery of etoposide by P-glycoprotein modulation: an in vitro, ex vivo and in vivo investigations. Drug Deliv. 2014: 1-12.
8. Liu YO, Fan JM, Wang XQ, Zhang Q. Preparation of sorafenib self-microemulsifying drug delivery system and its relative bioavailability in rats. J Chin Pharm Sci. 2011; 20(2): 164-170.
9. Wang S, Ye T, Zhang X, Yang R, Yi X. Myricetin loaded in microemulsion for oral drug delivery: formulation optimization, intestinal absorption in situ recirculation and in-vivo evaluation. Asian J Pharm Sci. 2012; 7(5): 293-300.
10. Hariharan S, Bhardwaj V, Bala I, Sitterberg J, Bakowsky U, Ravi Kumar MN. Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy. Pharm Res. 2006; 23(1): 184-195.
11. Arbós P, Campanero MA, Arangoa MA, Renedo MJ, Irache JM. Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties. J Control Release. 2003; 89(1): 19-30.
12. Joshi G, Kumar A, Sawant K. Enhanced bioavailability and intestinal uptake of Gemcitabine HCl loaded PLGA nanoparticles after oral delivery. Eur J Pharm Sci. 2014; 60: 80-89.
13. Griffin BT, O'Driscoll CM. Opportunities and challenges for oral delivery of hydrophobic versus hydrophilic peptide and protein-like drugs using lipid-based technologies. Ther Deliv. 2011; 2(12): 1633-1653.
14. Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci. 2000; 11 Suppl 2: S93-S98.
15. Nanjwade BK, Patel DJ, Udhani RA, Manvi FV. Functions of lipids for enhancement of oral bioavailability of poorly water-soluble drugs. Sci Pharm. 2011; 79(4): 705-727.
16. Lei Y, Qi J, Nie S, et al. Solid self-nanoemulsifying cyclosporine A pellets prepared by fluid-bed coating: stability and bioavailability study. J Biomed Nanotechnol. 2012; 8(3): 515-521.
17. Italia JL, Bhatt DK, Bhardwaj V, Tikoo K, Kumar MN. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J Control Release. 2007; 119(2): 197-206.
18. Beauchesne PR, Chung NS, Wasan KM. Cyclosporine A: a review of current oral and intravenous delivery systems. Drug Dev Ind Pharm. 2007; 33(3): 211-220.
19. Onoue S, Sato H, Ogawa K, et al. Improved dissolution and pharmacokinetic behavior of cyclosporine A using high-energy amorphous solid dispersion approach. Int J Pharm. 2010; 399(1-2): 94-101.
20. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 1995; 13(3): 129-134.
21. Sharma P, Varma MV, Chawla HP, Panchagnula R. Relationship between lipophilicity of BCS class III and IV drugs and the functional activity of peroral absorption enhancers. Farmaco. 2005; 60(11-12): 870-873.
22. Tjia JF, Webber IR, Back DJ. Cyclosporin metabolism by the gastrointestinal mucosa. Br J Clin Pharmacol. 1991; 31(3): 344-346.
23. Tarr BD, Yalkowsky SH. Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. Pharm Res. 1989; 6(1): 40-43.
24. Sato H, Kawabata Y, Yuminoki K, et al. Comparative studies on physicochemical stability of cyclosporine A-loaded amorphous solid dispersions. Int J Pharm. 2012; 426(1-2): 302-306.
25. Liu C, Zhu S, Zhou Y, Wei Y, Pei Y. In situ intestinal absorption of cyclosporine A solid dispersion in rats. Drug Dev Ind Pharm. 2008; 34(6): 627-631.
26. Nakarani M, Patel P, Patel J, Patel P, Murthy RS, Vaghani SS. Cyclosporine a-nanosuspension: formulation, characterization and in vivo comparison with a marketed formulation. Sci Pharm. 2010; 78(2): 345-361.
27. Guan P, Lu Y, Qi J, et al. Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. Int J Nanomedicine. 2011; 6: 965-974.
28. Müller RH, Runge S, Ravelli V, Mehnert W, Thünemann AF, Souto EB. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm. 2006; 317(1): 82-89.
29. Tian Z, Yi Y, Yuan H, et al. Solidification of nanostructured lipid carriers (NLCs) onto pellets by fluid-bed coating: preparation, in vitro characterization and bioavailability in dogs. Powder Technol. 2013; 247(Complete): 120-127.
30. Lei Y, Lu Y, Qi J, et al. Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility. Int J Nanomedicine. 2011; 6: 795-805.
31. Anand P, Nair HB, Sung B, et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol. 2010; 79(3): 330-338.
32. Mora-Huertas CE, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery. Int J Pharm. 2010; 385(1-2): 113-142.
33. Lai J, Lu Y, Yin Z, Hu F, Wu W. Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. Int J Nanomedicine. 2010; 5: 13-23.
34. Goddeeris C, Coacci J, Van den Mooter G. Correlation between digestion of the lipid phase of smedds and release of the anti-HIV drug UC 781 and the anti-mycotic drug enilconazole from smedds. Eur J Pharm Biopharm. 2007; 66(2): 173-181.
35. Williams HD, Trevaskis NL, Yeap YY, Anby MU, Pouton CW, Porter CJ. Lipid-based formulations and drug supersaturation: harnessing the unique benefits of the lipid digestion/absorption pathway. Pharm Res. 2013; 30(12): 2976-2992.
36. Sahana DK, Mittal G, Bhardwaj V, Kumar MN. PLGA nanoparticles for oral delivery of hydrophobic drugs: influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug. J Pharm Sci. 2008; 97(4): 1530-1542.
37. Zhao B, Yang LJ, Wang JC, Zhang Q. Studies on in vitro release of cyclosporine A-loaded microspheres. J Chin Pharm Sci. 2007; 16(4): 252-256.
38. Liu C, Wu J, Shi B, Zhang Y, Gao T, Pei Y. Enhancing the bioavailability of cyclosporine a using solid dispersion containing polyoxyethylene (40) stearate. Drug Dev Ind Pharm. 2006; 32(1): 115-123.
39. Ling G, Zhang P, Zhang W, et al. Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. J Control Release. 2010; 148(2): 241-248.
40. Gupta PN, Khatri K, Goyal AK, Mishra N, Vyas SP. M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J Drug Target. 2007; 15(10): 701-713.
41. Sarti F, Perera G, Hintzen F, et al. In vivo evidence of oral vaccination with PLGA nanoparticles containing the immunostimulant monophosphoryl lipid A. Biomaterials. 2011; 32(16): 4052-4057.
42. Beloqui A, Solinís MÁ, Gascón AR, del Pozo-Rodríguez A, des Rieux A, Préat V. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J Control Release. 2013; 166(2): 115-123.
43. Martin-Banderas L, Durán-Lobato M, Muñoz-Rubio I, Alvarez-Fuentes J, Fernández-Arevalo M, Holgado MA. Functional PLGA NPs for oral drug delivery: recent strategies and developments. Mini Rev Med Chem. 2013; 13(1): 58-69.
44. Wang T, Bai J, Jiang X, Nienhaus GU. Cellular Uptake of nanoparticles by membrane penetration: a study combining confocal microscopy with FTIR spectroelectrochemistry. ACS Nano. 2012; 6(2): 1251-1259.
45. Vácha R, Martinez-Veracoechea FJ, Frenkel D. Receptor-mediated endocytosis of nanoparticles of various shapes. Nano Lett. 2011; 11(12): 5391-5395.
46. Xu A, Yao M, Xu G, et al. A physical model for the size-dependent cellular uptake of nanoparticles modified with cationic surfactants. Int J Nanomedicine. 2012; 7: 3547-3554.
47. Wang K, Lu Y, Qi J, Yin Z, W. W. Comparative study on oral bioavailability of cyclosporine A-loaded solid dispersion and nanosuspension. J Chin Pharm Sci. 2014; 45(4): 354-358.
48. Roger E, Lagarce F, Garcion E, Benoit JP. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J Control Release. 2009; 140(2): 174-181.
49. Sachs-Barrable K, Lee SD, Wasan EK, Thornton SJ, Wasan KM. Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections. Adv Drug Deliv Rev. 2008; 60(6): 692-701.
50. Cuiné JF, McEvoy CL, Charman WN, et al. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. J Pharm Sci. 2008; 97(2): 995-1012.
51. Larsen AT, Ohlsson AG, Polentarutti B, et al. Oral bioavailability of cinnarizine in dogs: relation to SNEDDS droplet size, drug solubility and in vitro precipitation. Eur J Pharm Sci. 2013; 48(1-2): 339-350.